Pyronaridine is a new antimalarial agent developed in China. In this randomized, unblinded study, the safety, tolerance, and clinical efficacy of pyronaridine (n Å 44) were evaluated and compared with those of chloroquine (n Å 44), the standard first-line antimalarial drug in most of Africa, in 88 Cameroonian children with acute uncomplicated falciparum malaria. The target sample size was determined to detect a 35% difference in in vivo resistance between the two treatment groups, with 95% power. Clinical and parasitological responses were monitored for 14 days on an outpatient basis. Seven children (3 treated with pyronaridine and 4 treated with chloroquine) were lost to follow-up and were excluded from the analysis. All 41 patients treated with pyronaridine were cured. Treatment failure was observed in 16 (40%) of the 40 children treated with chloroquine. In vitro assays indicated that 23 of 40 clinical isolates obtained from patients treated with pyronaridine were resistant in vitro to chloroquine. Side effects associated with pyronaridine intake were minor and transient. Pyronaridine is safe and well tolerated by symptomatic Cameroonian children, and it is highly efficacious in Africa, where chloroquine resistance is well established.
Plasmodium falciparum malaria is one of the major causes
Health Organization (WHO) [3, 4] . The safety of other new candidate antimalarial drugs, such as atovaquone and benfluof morbidity and mortality among children in sub-Saharan Afmetol, has not been evaluated for children [5, 6] . rica and is responsible for Ç2 million deaths per year [1] . Only
Despite the spread and development of chloroquine resisa few drugs are currently available to treat malarial infections tance in the entire sub-Saharan Africa, chloroquine is still the in children. These antimalarial drugs include chloroquine, drug of choice for the treatment of acute uncomplicated falcipaamodiaquine, quinine, sulfadoxine-pyrimethamine (for chilrum malaria in indigenous populations in most African coundren ú2 months old), mefloquine (for children ú3 months old tries [7] . Sulfadoxine-pyrimethamine is the first-line antimalarand/or weighing ú5 kg), and halofantrine (for children ú1 ial drug in some East African countries where the proportion year old and/or weighing ú10 kg) [2] . Each of these standard of chloroquine resistance has reached high levels. In Cameroon, antimalarial drugs has important disadvantages, such as reCentral Africa, the Ministry of Public Health advocates the use duced clinical efficacy against P. falciparum due to drug resisof chloroquine or amodiaquine for first-line treatment. This tance in many parts of the world (chloroquine, amodiaquine, option to use chloroquine, despite a relatively high rate of and sulfadoxine-pyrimethamine); frequent side effects (quichloroquine therapeutic failure (40% -60%) in Cameroonian nine); risk of major adverse reactions (sulfadoxine-pyrimethadults, as shown in recent studies [8, 9] , is based on several amine and mefloquine); and high cost (quinine, mefloquine, reasons, including good tolerance, safety even in children and and halofantrine). Some of the new compounds derived from pregnant women, low cost, and wide availability even in remote artemisinin (artesunate, artemether, and arteether) have been villages. administered to children, but their use for the treatment of There are no reliable recent clinical data on chloroquine malaria in African children is not recommended by the World efficacy in symptomatic children in Cameroon. The secondand third-line antimalarial drugs in Cameroon are sulfadoxinepyrimethamine and quinine, respectively. Other new commer-oon, largely because sulfadoxine-pyrimethamine and quinine Pyronaridine, a benzonaphthyridine derivative that has a chemicontained 100 mg of base), manufactured at the Hangzhou Minsheng Pharmaceutical Factory (Shanghai, China; batch no. cal structure similar to those of mepacrine and amopyroquine, is a new candidate antimalarial compound synthesized in China in 010293) and provided through the courtesy of Professor Chen Chang (Institute of Parasitic Diseases, Chinese Academy of 1970 [11, 12] . It has been used to treat P. falciparum and Plasmodium vivax infections in China for ú20 years. Preliminary in vitro Preventive Medicine, Shanghai). The doses were administered under supervision. The only other medication given during the studies using African, Cambodian, and Thai clinical isolates of P. falciparum have shown the high activity of pyronaridine first 3 days of treatment was aspirin. Oral antihistamines were administered on day 2 to patients complaining of pruritus. [13] [14] [15] [16] . Experimental studies using rodent malaria models have also shown the efficacy and low toxicity of pyronaridine [17, 18] . Subsequent clinical studies conducted in indigenous adult patients Clinical Assessment between 16 and 65 years of age have shown that pyronaridine is safe and highly efficacious against P. falciparum infections in
The patients' clinical condition and parasite density were monitored on days 0, 1, 2, 3, 4, 7, and 14 on an outpatient areas in Cameroon and Thailand where chloroquine-resistant strains are endemic [9, 19] .
basis. Daily parasite density was monitored by preparation of Giemsa-stained thick blood smears from fingerprick blood samThe aims of our present study were to determine the tolerance and safety of pyronaridine and compare its efficacy with ples. Parasite density was calculated by counting the number of asexual parasites per 500 WBCs and was expressed as the that of chloroquine in a randomized study in symptomatic African children between 5 and 15 years old.
number of parasites/mL, based on the WBC count of the patient. Thick blood smears were considered negative if no asexual parasite was seen after 1,000 WBCs were counted. Complete Patients and Methods blood cell counts and blood chemistry tests were repeated on day 7.
Participants
Clinical efficacy was evaluated by determining fever clear-A total of 88 African children with malaria who resided in ance time, parasite clearance time, and clinical and parasitologYaoundé, Cameroon, were enrolled in the study in 1996. Incluical responses, on the basis of the 1994 WHO classification sion criteria included an age of between 5 and 15 years, fever scheme [22] . Fever clearance time was defined as the time at consultation (or history of fever within the past 24 hours), from the onset of treatment until the body temperature remained monoinfection with P. falciparum (parasite density, ú5,000 õ37.5ЊC. Parasite clearance time was defined as the time until asexual parasites/mL of blood), no recent history of selfa thick-blood smear became negative (and remained negative medication with antimalarial drugs (as confirmed by a negative until day 14). Saker-Solomons urine test [20] ), easy access to health services According to the 1994 WHO scheme, the patients' clinical in Yaoundé for daily monitoring, and informed consent by the and parasitological responses were classified into three levels. patient's guardian. Patients with signs and symptoms of severe Treatment success was the absence of clinical relapse within and complicated malaria, as defined by the WHO [21] , severe 14 days of treatment, with or without asymptomatic, persistent, anemia (hemoglobin level, õ5.0 g/dL), or moderate or severe or recurrent parasitemia. Clinical relapse within 14 days of malnutrition were excluded. treatment was indicative of treatment failure. This response Venous blood samples (5 mL) were obtained before treatwas considered either early treatment failure, defined by a posiment for microscopic examination of smears, in vitro drug tive blood smear and persistent fever on day 3 or worsening susceptibility assays, and hematologic and biochemical tests.
of the clinical condition before day 3, or late treatment failure, Giemsa-stained thin blood smears were examined under a defined by persistent or recurrent parasitemia and recurrent microscope for identification of species and determination fever after day 3, following initial resolution of fever on or of parasite density. Parasitized erythrocytes were counted before day 3. against 5,000 erythrocytes, and parasite density was calcuParasitological response was graded as follows: response lated from the RBC count and expressed as number of asex-''C'' (a positive parasite count on day 3 was ú25% of pretreatual parasites/mL. ment density on day 0, or alternative antimalarial treatment was required on or before day 3); response ''B'' (a positive parasite count on day 3 was õ25% of pretreatment density, and Treatment either the count was positive on day 7 or alternative antimalarial treatment was required between days 3 and 7); and response Patients were randomly assigned in blocks to receive either a 25-mg/kg dosage of chloroquine phosphate (10 mg/kg on ''A'' (a parasite count was negative on or before day 3 or positive on day 3 at õ25% of pretreatment level, and it was days 0 and 1; 5 mg/kg on day 2) or a 32-mg/kg dosage of pyronaridine (16 mg/kg on day 0, in two divided doses; 8 negative thereafter until day 14). Treatment failure was an indication for alternative therapy. For this study, oral halofanmg/kg on days 1 and 2). Pyronaridine tetraphosphate was administered in the form of enteric coated tablets (each tablet trine (total dose of 24 mg of base/kg, in three divided doses / 9c4a$$ap36 03-10-98 10:32:45 cida UC: CID at 6-hour intervals) in the form of tablets or oral suspension tively. Paired data were analyzed by the Wilcoxon signed-rank test. The two-sided P value was fixed at .05 for significance. was administered.
Results

In Vitro Assay Pretreatment Parameters
The in vitro drug susceptibility assay was performed on the Of the 88 patients enrolled in the study, 81 completed the clinical isolates, with use of the day 0 venous blood sample.
14-day follow-up (dropout rate, 8%). Three patients in the The assay for chloroquine and pyronaridine susceptibility was pyronaridine group and four in the chloroquine group were lost based on the incorporation of tritium-labeled hypoxanthine as to follow-up. Of the remaining 81 children with malaria, 41 an index of parasite growth [16] . The results of the assay were treated with pyronaridine and 40 were treated with chlowere analyzed by a linear regression of parasite growth, plotted roquine. The pretreatment clinical and laboratory characterisagainst the logarithm of drug concentrations. The in vitro drug tics of the patients in the two treatment groups were comparable response was expressed as the 50% inhibitory concentration (table 1) . The children, 44 males and 37 females, between 5 (IC 50 ), defined as the drug concentration at which 50% of paraand 15 years old and weighing between 20 and 66 kg, consulted site growth was inhibited in comparison with growth in the spontaneously at the Nlongkak Catholic missionary dispensary drug-free control wells. The threshold IC 50 value for in vitro after an average of 3 -4 days of illness. The mean initial temperresistance to chloroquine was fixed at ú100 nM. Because of ature was 38.3ЊC and the mean initial level of parasitemia was the high in vitro activity of pyronaridine and absence of in 103,000 asexual parasites/mL of blood (range, 7,590 -609,600 vitro/in vivo correlation data on patients failing to respond to parasites/mL). pyronaridine, its in vitro resistance level is still undefined.
Clinical Efficacy Statistical Analysis
In the pyronaridine group, all 41 patients responded favorably to the treatment with apyrexia and negative thick-blood The study was designed to detect a difference in clinical resistance of 35% with 95% power. Statistical analysis of quansmears on days 7 and 14, i.e., a treatment-success clinical response and a parasitological response A (table 2) . The mean titative and proportional data of the two treatment groups was done with the Mann-Whitney U-test and the x 2 test, respecfever clearance and parasite clearance times in these 41 patients cell count, and blood chemistry findings were normal and were * Pyronaridine was more effective than chloroquine (clinical response, P Å .0001; parasitological response, P Å .0001; x 2 test).
not suggestive of an identifiable infectious origin of the low- † Fever clearance and parasite clearance times in the chloroquine group are grade fever, except for an elevated percentage of lymphocytes based on data for patients responding with treatment success (n Å 23; minus one patient who developed an unidentified febrile illness during chloroquine therapy) and parasitological response A (n Å 21), respectively. ‡ In vitro susceptibility was defined by an IC 50 of õ100 nM and resistance by an IC 50 of ú100 nM. were 35.7 hours and 72.6 hours, respectively. None of the patients was febrile on day 3.
A rapid fall in level of parasitemia was observed in all patients (figure 1). On day 1, the parasitemia diminished, on the average, to 82.7% of the initial parasitemia; the lowest fall in parasitemia was to 16% of the initial parasitemia. On day 2, the average decrease in parasitemia was to 98.5% of the initial parasitemia, and the least decrease was to 86%.
Eight of 41 patients had negative blood smears from days 2 to 14. On day 3, 32 patients were parasite-free; among the nine positive patients, the highest parasitemia level corresponded to 0.25% of the initial parasitemia. The range of parasitemia levels in nine patients with positive smears on day 3 was 24 -648 03-10-98 10:32:45 cida UC: CID (55% on day 0; 62% on day 7) compared with that of neutro-(P ú .05). The absolute number of neutrophils diminished while that of lymphocytes increased in both treatment groups. phils.
The mean fever clearance time in patients treated successHowever, the absolute number of neutrophils and lymphocytes on days 0 and 7 did not vary significantly between the two fully with chloroquine (n Å 23; minus one patient whose persistent fever was due to an unidentified cause other than malaria) groups. Compared with the eosinophil and reticulocyte counts on day 0, a significant increase was noted in both treatment was 31.3 hours. In these 23 patients responding favorably to chloroquine, apyrexia was noted on day 3. The mean parasite groups on day 7. On day 7, the platelet count increased two-to three-fold clearance time in patients with negative blood smears on days 7 and 14 (parasitological response A; n Å 21) was 70.9 hours.
the initial value in both treatment groups. Liver function tests showed a slight decrease in transaminase levels and alkaline phosphatase values and a two-to three-fold decrease in total
In Vitro Susceptibility and conjugated bilirubin values in both groups on day 7. Renal function tests showed no significant change in blood creatinine In vitro drug assays showed pyronaridine was highly active and a two-fold decrease in blood urea nitrogen on day 7 in against both chloroquine-susceptible and chloroquine-resistant both the pyronaridine and chloroquine treatment groups. and headache (4 of 41; 9.8%). Other complaints included dizziness (n Å 2), nausea (n Å 2), vomiting (n Å 3), palpitation (n Å 3), and pruritus (n Å 2). None of these mild side effects
Hematology and Biochemistry required symptomatic treatment. Pruritus occurred in only two of 10 pyronaridine-treated patients known to have a past history Pretreatment and day 7 posttreatment complete blood cell count and blood chemistry findings in the pyronaridine and of pruritus due to chloroquine. Patients in the chloroquine group complained most frequently of pruritus (19 of 40; 48%). chloroquine groups were compared (table 3). The mean hemoglobin concentration and WBC count in pyronaridine-treated Of the 19 patients complaining of itchiness, 9 claimed to have had pruritus after chloroquine intake in the past, while and chloroquine-treated patients did not vary significantly NOTE. Within-group comparison between day 0 and day 7 values showed significant differences (P õ .05) in all hematology and biochemistry values, except for hemoglobin, WBC count, transaminase, alkaline phosphatase, and serum creatinine values in both the chloroquine-treated and pyronaridine-treated groups.
/ 9c4a$$ap36
03-10-98 10:32:45 cida UC: CID isolates or the level of acquired immunity in the different patient populations [19] . However, since a considerable number of Thai patients (46 of 101; 46%) had a positive urine test for antimalarial drugs prior to pyronaridine treatment and since the other 10 patients denied having had pruritus in previous antagonistic or synergistic interactions between pyronaridine antimalarial treatment. Other common mild side effects in paand other drugs are not known, the real clinical efficacy of tients treated with chloroquine included abdominal pain, naupyronaridine alone may be questioned until further confirmasea, and vomiting.
tory studies are done in Thailand.
The side effects observed in the pyronaridine and chloroquine groups were similar, except for the significant number Discussion of children complaining of mild, transient gastrointestinal problems in the pyronaridine-treated group and pruritus in the chloThe results of the present study indicate that pyronaridine is highly efficacious in treating acute uncomplicated falciparum roquine-treated group. Few children complained of nausea, vomiting, headache, and palpitation. Most of these symptoms, malaria in Cameroonian children with malaria aged between 5 and 15 years. All patients showed signs of rapid clinical except for the well-known drug-induced pruritus in darkskinned patients, are also associated with malarial infection, improvement. Apyrexia was attained within 72 hours after the first oral dose. Parasites were undetectable in thick-blood and it is therefore difficult to differentiate between druginduced side effects and symptoms due to malaria. In all cases, smears for 32 (78%) of 41 patients on day 3 and for all patients on day 4. No clinical or parasitological recrudescence was patients responding favorably according to the parasitological criteria ceased to complain of these mild symptoms within the observed during the 14-day follow-up in children treated with pyronaridine. Pyronaridine, at a total dose of 32 mg/kg, adminfirst 3 or 4 days of treatment. Except for pruritus, no specific treatment was required. Thus, our study suggests that pyronariistered in four divided doses over 3 days, was well tolerated; there were only a few minor side effects, which did not require dine is well tolerated by symptomatic children. Blood chemistry and complete blood cell count findings any specific treatment.
In contrast, some children (five of 40; 12.5%) treated with showed similar changes in both the chloroquine and pyronaridine groups. Among the 41 African children treated with pyrothe standard-dose regimen of chloroquine showed signs of rapid clinical deterioration, necessitating alternative treatment within naridine, two had normal levels of transaminases before treatment and developed a two-to three-fold increase in the level 72 hours after the first dose of chloroquine. Other children (11 of 40) had some clinical and/or parasitological improvement of serum aspartate aminotransferase (serum AST; 62 -67 IU/L) on day 7. In another child, the initial serum AST level during the first 6 days but required an alternative treatment because of persistent or recurrent fever and parasitemia. A total (57 IU/L) was slightly elevated and rose to a two-fold level on day 7. In these three patients, serum alanine aminotransferase of 16 patients (40%) failed to respond to chloroquine therapy.
The present study followed the latest available WHO in vivo (serum ALT) values remained within the normal ranges. Among African adults treated with pyronaridine, four distest method, which requires follow-up for 14 days [22] . A 28-day follow-up may have detected cases of late recrudesplayed slight increases (53 -74 IU/L) on day 7 and another three had a considerable increase (two-fold to three-fold; cence, but in Africa reappearance of asexual parasites after day 14 may be due to either reinfection or recrudescence. Neverthe-17-fold in one patient [105 -403 IU/L]) in transaminase levels on day 7 [9] . In adult and pediatric patients whose blood chemless, our results were similar to those of other studies of pyronaridine.
istry tests were repeated on day 14, these values returned to / 9c4a$$ap36 03-10-98 10:32:45 cida UC: CID within the normal range or decreased considerably on day 14. roquine and may be a rational choice to replace chloroquine. Unlike chloroquine, pyronaridine does not have a bitter taste, Thus, although some concern has been raised about the posttreatment increase of transaminase values in patients treated which is an important advantage in administering the drug to children. Furthermore, pruritus is less common after pyronariwith pyronaridine [19] , our data show that only a few patients developed a transient rise in AST and ALT levels. dine treatment. This is an additional advantage that may enhance compliance in sub-Saharan Africa. Pyronaridine is also Hematologic examination showed no adverse effect of pyronaridine on the RBC and WBC counts on days 0 and 7. Pyronarless expensive than other available drugs that are effective against chloroquine-resistant parasites, such as oral quinine idine does not exhibit any inhibitory effect on reticulocyte formation. Although an inversion of the neutrophil:lymphocyte administered in a 5-day course, mefloquine, or halofantrine. Despite these advantages of pyronaridine, more preclinical differential count was observed in children treated with pyronaridine and chloroquine, there was a slight change in the and clinical data are needed for the development and regulatory approval of pyronaridine in countries other than China before absolute WBC count between days 0 and 7. The absolute eosinophil count increased about fourfold in some patients treated this drug can be widely recommended for the treatment of acute uncomplicated falciparum malaria [30, 31] . Furthermore, with pyronaridine or chloroquine.
Eosinophilia after malaria treatment with quinine or mefloquine a suitable partner for combination therapy with pyronaridine needs to be identified to prevent or delay the emergence of has been previously reported to occur in Thai patients during the convalescence period (about 4 weeks post-treatment) but not durpyronaridine resistance [32 -35] . The safety and tolerance of pyronaridine in young children less than 5 years old and in ing the acute phase (until day 7), independently of intestinal helminths and cytokine levels [23] . The mechanism of eosinophil pregnant women should also be assessed. activation and its clinical and immunologic significance are currently unknown, but the relatively early eosinophilia in African
